About elranatamab
BCMA-directed bispecific antibody
Used for
- Treats adults with relapsed or refractory multiple myeloma after several previous treatments.
Usual adult dose
Given under the skin by a healthcare professional, with step-up doses followed by weekly dosing; dosing may later become every two weeks.
Common side effects
- Cytokine release syndrome, including fever and low blood pressure
- Low blood cell counts, including infections and anemia
- Injection-site reactions
- Fatigue, diarrhea, or nausea
Important warnings
- Cytokine release syndrome and serious neurologic problems can occur, especially during initial doses.
- Infections can be severe; blood counts and symptoms require monitoring.
- Treatment is restricted through a safety program because of these risks.
- May cause harm to an unborn baby; effective contraception is advised during treatment and for four months afterward.
Pregnancy
May cause fetal harm. Human pregnancy data are limited; effective contraception is advised during treatment and for four months after the last dose.
Breastfeeding
It is not known whether elranatamab passes into breast milk. Breastfeeding is not recommended during treatment and for four months after the last dose.
Interactions
- May reduce the effectiveness of some CYP450-metabolized medicines; clinicians may monitor or adjust these drugs, especially after starting treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.